Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
Three of India´s large pharmaceutical manufacturers, Dr Reddy's,
Ranbaxy Laboratories and Shilpa Medicare have just announced new
merger and acquisition (M&A) deals.
